US FDA publishes list of drugs undergoing safety scrutiny
This article was originally published in Scrip
The US FDAhas embarked on a new method for disclosing when marketed drugs are undergoing heightened safety scrutiny by the agency. However, the initiative has raised questions about the scarcity of information released, the potential impact on patient use of medicines, and negative ramifications for product sponsors.
You may also be interested in...
Under certain circumstances, potential clinical trial participants may be able to provide informed consent by writing on a blank piece of paper that they voluntarily agree to participate in a given protocol and texting or emailing a photo of the signed document to the investigator, US FDA says in latest guidance update.
Timelines in the CID program are tight, and sponsors should have a ‘fully baked’ trial design before heading into their first meeting with the agency, industry reps say; agency needs more simulation data from participating sponsors earlier and is working to ensure continuity for firms after the second of two meetings allowed under the program.
Oncology Center of Excellence’s Paul Kluetz says agency intends to explore the effects of decentralization, remote assessments and other approaches adopted mid-stream on safety evaluations, missing data and endpoint variability.